Health Care Reform For Pfizer Equals $800 Million Revenue Hit In 2012
Executive Summary
The addition of legacy Wyeth products helped cushion Pfizer's top-line in the first quarter, and synergies stemming from the integration could help the company absorb the cost of health care reform
You may also be interested in...
For Bristol, Onglyza Disappoints And Health Care Reform Takes A Toll
The new health care reform statute will have a significant impact on Bristol-Myers Squibb's sales in 2010 and 2011, the company said during a first quarter sales and earnings call April 29 in which the drug maker announced it is revising earnings guidance for the year as a result
ACIP's Support Of FDA-Approved Prevnar 13 Creates Opportunity For Larger Market
FDA approves Pfizer's Prevnar 13 vaccine and ACIP's recommendations set the stage for a broadened indication and a blockbuster product.
Pfizer Lowers Targeted Revenues for 2012; Wall Street Remains Skeptical
Pfizer's touts growth plans in emerging markets as the pharma prepares for the onset of Lipitor generics.